Your browser is no longer supported. Please, upgrade your browser.
AZN AstraZeneca PLC daily Stock Chart
AstraZeneca PLC
Index- P/E51.19 EPS (ttm)0.86 Insider Own0.50% Shs Outstand2.62B Perf Week1.22%
Market Cap115.71B Forward P/E21.92 EPS next Y2.01 Insider Trans0.00% Shs Float2.61B Perf Month1.29%
Income2.19B PEG3.18 EPS next Q0.45 Inst Own18.70% Short Float0.38% Perf Quarter10.00%
Sales23.07B P/S5.02 EPS this Y-9.60% Inst Trans0.02% Short Ratio2.93 Perf Half Y13.74%
Book/sh5.17 P/B8.54 EPS next Y11.65% ROA3.60% Target Price46.90 Perf Year12.92%
Cash/sh2.38 P/C18.52 EPS next 5Y16.10% ROE18.10% 52W Range35.30 - 46.22 Perf YTD16.19%
Dividend1.40 P/FCF- EPS past 5Y-3.60% ROI10.90% 52W High-4.52% Beta0.47
Dividend %3.17% Quick Ratio0.70 Sales past 5Y-3.10% Gross Margin80.30% 52W Low25.01% ATR0.67
Employees64400 Current Ratio0.90 Sales Q/Q13.00% Oper. Margin15.20% RSI (14)51.99 Volatility1.14% 1.19%
OptionableYes Debt/Eq1.45 EPS Q/Q-64.10% Profit Margin9.50% Rel Volume0.71 Prev Close43.79
ShortableYes LT Debt/Eq1.32 EarningsOct 24 BMO Payout161.60% Avg Volume3.43M Price44.13
Recom1.60 SMA200.10% SMA50-0.19% SMA2008.03% Volume2,431,467 Change0.78%
Apr-02-19Downgrade UBS Neutral → Sell
Feb-05-19Initiated Exane BNP Paribas Outperform
Jan-25-19Upgrade Shore Capital Hold → Buy
Dec-11-18Resumed Jefferies Hold
Oct-09-18Initiated Guggenheim Buy
Aug-16-18Downgrade Jefferies Buy → Hold
Mar-19-18Upgrade Jefferies Hold → Buy
Feb-06-18Reiterated Leerink Partners Mkt Perform $36 → $38
Feb-05-18Reiterated Bernstein Outperform $40 → $42
Jan-18-18Reiterated Leerink Partners Mkt Perform $33 → $36
Dec-29-17Upgrade JP Morgan Neutral → Overweight
Oct-16-17Upgrade Credit Suisse Neutral → Outperform
Sep-25-17Upgrade Exane BNP Paribas Neutral → Outperform
Sep-22-17Upgrade Bernstein Mkt Perform → Outperform
Sep-14-17Downgrade Liberum Buy → Hold
Sep-06-17Upgrade Natixis Bleichroeder Neutral → Buy
Aug-09-17Upgrade Investec Hold → Buy
Jul-28-17Downgrade Morgan Stanley Overweight → Equal-Weight
May-12-17Upgrade Credit Suisse Underperform → Neutral
Apr-10-17Downgrade Jefferies Buy → Hold
Oct-17-19 10:51AM  AstraZeneca Shares Trade Higher After FDA Grants Breast Cancer Drug Priority Review Benzinga
07:00AM  Trastuzumab Deruxtecan Granted FDA Priority Review for Treatment of Patients With HER2-positive Metastatic Breast Cancer Business Wire
03:18AM  UPDATE 1-AstraZeneca breast cancer treatment gets FDA priority review Reuters
02:29AM  AstraZeneca gets FDA priority review for experimental breast cancer drug Reuters
Oct-15-19 12:21PM  AbbVie, Bristol-Myers Squibb Getting the Most From Workers
Oct-14-19 02:00AM  ImaginAb signs multi-party collaboration agreement with three global pharmaceutical companies to help further develop company's CD8 ImmunoPET technology PR Newswire
Oct-13-19 05:15PM  New Sanofi CEO Looks to Shake Things Up
Oct-09-19 04:05PM  Hedge Funds Are Undecided About AstraZeneca plc (AZN) Insider Monkey
Oct-07-19 12:32PM  Trio Wins Nobel for Oxygen Studies That Led to Anemia Drugs Bloomberg
11:06AM  Cheplapharm Arzneimittel GmbH -- Moody's downgrades Cheplapharm to B2; outlook stable Moody's
10:05AM  The Zacks Analyst Blog Highlights: J&J, AstraZeneca, Roche, Glaxo and Merck Zacks
08:23AM  AstraZeneca's Fasenra Gets FDA Nod for Self-Administration Zacks
07:48AM  AstraZeneca Launches Signature STEM Program to Empower Students to Live Healthier Lives and Inspire Future Scientists Business Wire
Oct-04-19 11:11AM  Pharma Stock Roundup: JNJ's Opioid Settlement, FDA Updates for AZN, GSK, MRK, RHHBY Zacks
07:00AM  FASENRA® (benralizumab) Approved in the US for Self-administration in a New Pre-filled Auto-injector, the FASENRA Pen Business Wire
03:06AM  FDA green lights AstraZeneca's asthma drug Fasenra for self-administration Reuters
Oct-03-19 01:23PM  Top Research Reports for Bank of America, Home Depot & Philip Morris Zacks
10:16AM  Viela Bio officially goes public American City Business Journals
Oct-02-19 11:36AM  Agios' Tibsovo Improves Survival in Cholangiocarcinoma Study Zacks
09:33AM  Why this UC Berkeley gene therapy spinout is targeting a $100 million IPO American City Business Journals
07:05AM  AstraZeneca's Triple-Combo COPD Inhaler Gets CRL From FDA Zacks
Oct-01-19 09:51AM  AstraZeneca/Merck's Lynparza Positive in Prostate Cancer Study Zacks
06:13AM  Brexit stockpiling shows up in manufacturing data and bakery results MarketWatch
05:33AM  Does AstraZeneca's (LON:AZN) Share Price Gain of 66% Match Its Business Performance? Simply Wall St.
04:49AM  UPDATE 2-Weak U.S., euro zone data push European shares lower Reuters
03:19AM  AstraZeneca sells acid reflux drug rights to Germany's Cheplapharm Reuters
02:43AM  UPDATE 1-AstraZeneca's combo lung disease therapy fails to win FDA approval Reuters
02:17AM  AstraZeneca's combo lung disease therapy falls short of FDA approval Reuters
Sep-30-19 11:13AM  Glaxo's Zejula Betters PFS in First-Line Ovarian Cancer Study Zacks
10:59AM  AstraZeneca/Merck's Lynparza Improves PFS in Frontline Study Zacks
10:59AM  LYNPARZA (olaparib) More Than Doubled the Time Without Radiographic Disease Progression in Patients With BRCA1/2- or ATM-Mutated Metastatic Castration-Resistant Prostate Cancer Business Wire
10:30AM  AstraZeneca strengthens Lynparza push with prostate cancer data Reuters
08:50AM  Roche's (RHHBY) Rituxan Receives FDA Nod for Label Expansion Zacks
05:23AM  AstraZeneca, Merck ovarian cancer treatment improves progression-free survival Reuters
03:07AM  UPDATE 1-AstraZeneca, Merck ovarian cancer treatment improves progression-free survival Reuters
02:29AM  AstraZeneca, Merck cancer treatment attains meaningful improvement in progression-free survival Reuters
Sep-29-19 03:01PM  The Week Ahead In Biotech (Sept. 29-Oct. 5): Conference Presentations, IPOs Hit Top Gear Benzinga
Sep-28-19 12:48PM  TAGRISSO Is the Only 1st-line Treatment for EGFR-Mutated Non-Small Cell Lung Cancer to Deliver a Median Overall Survival of More Than Three Years Business Wire
12:46PM  UPDATE 1-Results of GSK and AstraZeneca trials may widen ovarian cancer drug use Reuters
12:23PM  LYNPARZA (olaparib) Improved the Time Women Lived Without Disease Progression to 22 Months in the Broad Population and 37 Months in HRD-positive Patients as 1st-line Maintenance Treatment with Bevacizumab for Newly Diagnosed Advanced Ovarian Cancer Business Wire
10:30AM  Separate GSK, AstraZeneca trial results may widen ovarian cancer drug use Reuters
01:45AM  Data may widen market for AstraZeneca and GSK ovarian cancer drugs Financial Times
Sep-27-19 01:47PM  Apple Hires AstraZeneca Chief Information Officer David Smoley Bloomberg
11:03AM  FibroGen Begins Study on Roxadustat for Chemo-Induced Anemia Zacks
Sep-26-19 02:53PM  BRILINTA Monotherapy in High-Bleeding Risk Patients Who Underwent PCI had Reduced Risk of Clinically Relevant Bleeding Than With Dual Antiplatelet Therapy in the TWILIGHT Trial Business Wire
12:38PM  Foreign Firms Recognized as Hottest Biotechs
12:10PM  Entrepreneur who sold past company for $2.7B raises funding for DFW startup American City Business Journals
11:45AM  Here's Why AstraZeneca (AZN) is Outperforming Its Industry Zacks
11:16AM  Tyme Initiates Pivotal Stage of Pancreatic Cancer Study Zacks
05:04AM  GSK, AstraZeneca rivalry takes centre stage at cancer conference Reuters
Sep-25-19 04:54PM  6 Guru Stocks With High Dividend Yields
10:53AM  Bristol-Myers' Opdivo Gains Positive CHMP View for New Dose Zacks
12:37AM  Bristol-Myers Squibb Company -- Moody's: China's rising demand for drugs will fuel foreign pharma companies' growth into 2023 Moody's
Sep-24-19 04:59PM  Zeneca Wilmington Inc. -- Moody's announces completion of a periodic review of ratings of AstraZeneca PLC Moody's
11:46AM  Bristol-Myers Squibb Company -- Moody's: China's rising demand for drugs will fuel foreign pharma companies' growth into 2023 Moody's
11:36AM  Clovis Gains Rights to Pre-Clinical Cancer Program for $12M Zacks
11:32AM  AstraZeneca Gets CHMP Nod for Forxiga/Onglyza Combo Tablet Zacks
11:12AM  Chinas Drug-Price Cuts Pressure Lipitor and Other Foreign Pills Bloomberg
Sep-22-19 04:22PM  The Week Ahead In Biotech: Spotlight On ESMO Conference Benzinga
Sep-20-19 11:54AM  FibroGen's Evrenzo Gets Nod in Japan for Anemia with CKD Zacks
08:41AM  Pharma Stock Roundup: FDA Approves Expanded Use of MRK/J&J's Drugs & Other Updates Zacks
Sep-19-19 02:31PM  Ironwood Amends Linzess Agreement with AstraZeneca in China Zacks
12:46PM  U.K. stocks snap three-day losing run MarketWatch
Sep-16-19 10:43AM  AstraZeneca's Farxiga Gets Fast Track Tag for Heart Failure Zacks
10:16AM  Biogen Stops Late-Stage Studies on Alzheimer's Candidate Zacks
08:33AM  Breast Cancer Drugs May Inflame Lungs Per FDA Safety Alert Zacks
07:30AM  FDA Grants Fast Track Designation for FARXIGA in Heart Failure Business Wire
03:23AM  AstraZeneca diabetes drug granted fast track status for heart failure treatment Reuters
Sep-13-19 10:08AM  Glaxo's Asthma Drug Nucala Gets FDA Nod for Pediatric Use Zacks
09:46AM  Pharma Stock Roundup: Pipeline/Regulatory Updates From GSK, PFE & Others Zacks
04:47AM  Roche Reports Positive Data on Tecentriq & NMOSD Drug (Revised) Zacks
Sep-12-19 05:46PM  Gilead Tops List of Most Innovative Drug Companies
09:09AM  Roche (RHHBY) Reports Positive Data on Tecentriq & MS Drug Zacks
Sep-11-19 05:47PM  East Bay company eyes first drug approval after decade-long journey American City Business Journals
03:50PM  Leaner Pfizer Positioned to Boost R&D Output
11:40AM  AVEO Surges on Favorable Updated OS Results on RCC Drug Zacks
11:13AM  Bristol-Myers' (BMY) Opdivo Shows Long-Term Survival Benefit Zacks
09:46AM  Lexicon (LXRX) Settles With Sanofi for $260M, Shares Rally Zacks
09:32AM  4 Big Drugmakers Boasting Impressive Oncology Pipelines Zacks
08:57AM  Should You Buy AstraZeneca PLC (LON:AZN) For Its Dividend? Simply Wall St.
Sep-10-19 11:41AM  ACADIA Surges on Early Success of Nuplazid Dementia Study Zacks
Sep-09-19 09:32PM  AstraZeneca's Executive VP Sees Upside, As China's Government Speeds Up New Drug Approval Bloomberg
07:00AM  IMFINZI Is First Immunotherapy to Show Both Significant Survival Benefit and Improved, Durable Responses in Extensive-Stage Small Cell Lung Cancer Business Wire
03:38AM  CORRECTED-AstraZeneca's Imfinzi prolongs survival in aggressive lung cancer Reuters
Sep-06-19 11:48AM  Novartis' Capmatinib Gets Breakthrough Therapy Tag From FDA Zacks
11:36AM  Pharma Stock Roundup: AGN's Opioid Settlement, Line Extension Nod in EU for MRK, JNJ Drugs Zacks
08:39AM  Roche's Tecentriq Combo Gets EU Nod for Difficult Lung Cancer Zacks
Sep-05-19 01:50PM  AstraZeneca's Tagrisso Gets Nod in China for First-Line NSCLC Zacks
12:52PM  Podcast: Why Big Pharma Is Betting on a New Biotech Therapy
11:12AM  Is the FDA Out to Get This $2.9 Billion Diabetes Drug Class? Motley Fool
Sep-04-19 10:32AM  Vertex (VRTX) Inks All-Cash Deal to Acquire Semma for $950M Zacks
Sep-03-19 03:05PM  5 things to know ahead of Viela Bios planned $150M IPO American City Business Journals
10:44AM  Companies to Watch: Roche gets more time for Spark deal, AstraZeneca shows promise in clinical trial, Snap get upgraded Yahoo Finance
10:26AM  Companies to Watch: Roche gets more time for Spark deal, AstraZeneca shows promise in clinical trial, Snap get upgraded Yahoo Finance Video
Sep-02-19 03:13PM  The Week Ahead In Biotech: Cardiology, Analyst Conferences In The Spotlight Benzinga
07:30AM  Pound tumbles as British factory output hits seven-year low ahead of Brexit showdown MarketWatch
12:53AM  Marks and Spencer heads for relegation from FTSE 100 Financial Times
Aug-30-19 02:56PM  Md. biotech files to go public with $150M offering American City Business Journals
01:50PM  AstraZeneca Spin-Off Viela Bio Files For IPO Benzinga
11:16AM  AstraZeneca's Lupus Drug Meets Primary Endpoint in Study Zacks
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, Symbicort Turbuhaler, and Tudorza Pressair for respiratory diseases; Fluenz FluMist/Tetra Quadrivalen and Synagis3 for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, and Vimovo for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. AstraZeneca PLC has a collaboration and license option agreement with Transgene SA for clinical development and commercialization of novel oncolytic immunotherapies; and with Ironwood Pharmaceuticals, Inc. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ASTRAZENECA PLC10% OwnerOct 07Buy19.00425,0008,075,00014,650,334Oct 09 04:53 PM
ASTRAZENECA PLC10% OwnerOct 22Buy5.00600,0003,000,0003,004,554Oct 24 04:16 PM